FATE News and Press, Fate Therapeutics Inc. From 07/21/20

As 2020 has demonstrated, the stock market can move in any direction in the short term. But as historical stock market data suggest, the stock market wields rock-solid wealth-building potential in the long run. That's why individual investors are best served by adopting a long-term mindset with ...

License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients Preclinical Data Published in the Journal Nature Biotechnology Demonstrate Allogeneic CAR T Cells Overcome Immune Rejection and Exhibit Durable ...

Nkarta (NASDAQ: NKTX ) had a big IPO, upsizing the number of shares sold to 14M from 10M. It also priced at $18 vs. the expected range of $16-$17. The offering raised $252M. More news on: Nkarta, Inc., Fate Therapeutics, Inc., CRISPR Therapeutics AG, Top stock market news, IPO News, Health...

The FDA has signed off on Fate Therapeutics' (NASDAQ: FATE ) IND to start clinical development of FT819, an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. More news on: Fate Therapeutics, Inc., Healthcare stocks news, Stocks on the m...

FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Fate...

Quick Take Nkarta ( NKTX ) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood and other cancer indications. NKTX is still at preclinical stage of ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

If you had invested $1,000 in shares of mid-cap biotech company Fate Therapeutics   (NASDAQ: FATE) when it IPO'd, you would have close to $4,823.33 as of markets' close on June 11. That's an astonishing return on investment of 397.5%. In context, the S&P 500 returned 78.8% over the ...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

Shares of Fate Therapeutics (NASDAQ: FATE) gained over 18% last month, according to data provided by S&P Global Market Intelligence . Most of the stock's gains in May can be traced to a single announcement by the cell-therapy developer.  On May 20, the development-stage company an...